REVIEW PAPER
Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy
Submission date: 2017-06-06
Final revision date: 2017-08-01
Acceptance date: 2017-08-02
Publication date: 2017-12-30
Cent Eur J Immunol 2017;42(4):377-382
KEYWORDS
pancreatic cancermalnutritiontumour angiogenesisoxidative stressmiRNAinflammationhigh-mobility group box 1 (HMBG1)
ABSTRACT
Pancreatic cancer, with a total five-year survival rate below 5%, represents a disease with a high level of malignancy. Some of the pancreatic cancer bad prognosis factors are nutrition disorders. Malnutrition, neither recognized nor properly referred to by the healthcare system, leads to well-documented negative health consequences in hospitalized patients including their impaired immunity, delayed post-surgery wound healing, a high risk of infectious complications, morbidity and mortality. There are numerous factors contributing to the development of pancreatic cancer, including telomerases, inflammation, angiogenesis, epigenetics and genetics factors, miRNA, pancreatic cancer stem cells. On the basis of molecular analyses, it has been established that precursor injuries may trigger pancreatic cancer when added to genetic alterations. Perhaps, combination of few presently used methods, like signal transduction modulated by K-ras, STAT3 activation, HMGB1 releasing, presence of oxidative stress and free radicals secretion, genes for proangiogenic growth factors activation or tissue-specific miRNA genes expression – will solve the problem of inadequate diagnostics.
REFERENCES (56)
2.
Chang JC, Kundranda M (2017): Novell diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 18: 667-681.
3.
Abreu FB, Liu X, Tsongalis GJ (2017): miRNA analysis in pancreatic cancer: the Dartmouth experience. Clin Chem Lab Med 55: 755-762.
4.
Lovanna J, Mallmann MC, Goncalves A, et al. (2012): Current knowledge on pancreatic cancer. Frontiers in Oncology 2: 1-24.
5.
Corbo V, Tortora G, Scarpa A (2012): Molecular pathology of pancreatic cancer: from bench to beside translation. Current Drug Targets 13: 744-752.
6.
Słotwiński R, Olszewski WL, Krasnodębski IW, et al. (2006): Changes in interleukin-6 and cytokines antagonists serum concentrations in patients after pancreatic cancer surgery receiving nutritional support. Centr Eur J Immunol 31: 25-30.
7.
Kondrup J, Allison SP, Elia M, et al. (2003): Educational, Clinical Practice Committee ESoP, enteral N. ESPEN guidelines for nutrition screening 2002. Clin Nutr 22: 415-421.
8.
McClave SA, Martindale RG, Vanek VW, et al. (2009): Guidelines for the provision and assessment of nutrition support therapy in the adult critically Ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. J Parenter Enteral Nutr 33: 277-316.
9.
Guerran C, Schuhmacher AJ, Canamero M, et al. (2007): Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
10.
Singh M, Maitra A (2007). Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 7: 9-19.
11.
Mimeault M, Brand RE, Sasson AA, et al. (2005). Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 31: 301-316.
12.
Mohammed A, Janakiram NB, Pant S, et al. (2015): Molecular targeted intervention for pancreatic cancer. Cancers 7: 1499-1542.
13.
Holmer R, Goumas FA, Waetzig GH, et al. (2014): Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int 13: 371-380.
14.
Philip B, Roland CL, Daniluk J, et al. (2013): A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145: 1449-1458.
15.
Zhang L, Li J, Zong L, et al. (2016): Reactive oxygen species and targeted therapy for pancreatic cancer. Oxid Med Cell Longev 2016: 1-9.
16.
Almoguera C, Shibata D, Forrester K, et al. (1988): Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
17.
Ogrunc M, Di Micco R, Liontos M, et al. (2014): Oncogene induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ 21: 998-1012.
18.
Edderkaoui M, Hong P, Vaquero EC, et al. (2005): Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am J Physiol Gastrointest Liver Physiol 289: G1137-G1147.
19.
Sawai H, Funahashi H, Okada Y, et al. (2005): Interleukin 1 enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Medical Science Monitor 11: BR343-BR350.
20.
Radomska-Leśniewska DM, Hevelke A, Skopiński P, et al. (2016): Reactive oxygen species and synthetic antioxidants as angiogenesis modulators: clinical implications. Pharmacol Rep 68: 462-471.
21.
Kim YM, Kim KE, Koch GY, et al. (2006): Hydrogen peroxide produced by angiopoietin-1 mediates angiogenesis. Cancer Res 66: 6167-6174.
22.
Kardech S, Ashkani-Esfahani S, Aliozadeh AM (2014): Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur J Pharmacol 2735: 150-168.
23.
Yiwei L, Sarkar FH (2016): MicroRNA targeted therapeutic approach for pancreatic cancer. Int J Biol Sci 12: 326-337.
24.
Friedman RC, Farh KK, Burge CB, et al. (2009): Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
25.
Lewis BP, Burge CB, Bartel DP (2005): Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
26.
Winter J, Jung S, Keller S, et al. (2009): Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11: 228-234.
27.
Cutts RJ, Gadaleta E, Hahn SA, et al. (2011): The Pancreatic expression database: 2011 update. Nucleic Acids Res 39: D1023-D1028.
28.
Munding JB, Adai AT, Maghnouj A, et al. (2012): Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 131: E86-E95.
29.
Jiang J, Lee EJ, Gusev Y, et al. (2005): Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33: 5394-5403.
30.
Volinia S, Calin GA, Liu CG, et al. (2006): A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
31.
Olson P, Lu J, Zhang H, et al. (2009): MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23: 2152-2165.
32.
Lee CH, Subramanian S, Beck AH, et al. (2009): MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4: e7314.
33.
Siuwah Tang BS, Jillian Bonaroti BS, Sebnem U, et al. (2013): Sweating the small stuff microRNAs and genetic changes define pancreatic cancer. Pancreas 42: 740-759.
34.
Feldmann G, Habbe N, Dhara S, et al. (2008): Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57: 1420-1430.
35.
Altaf M, Naveena JB (2015): Molecular Targeted Intervention for Pancreatic Cancer. Cancers 7: 1499-1542.
36.
Sood P, Krek A, Zavolan M, et al. (2006): Cell- type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 103: 2746-2751.
37.
Schultz NA, Dehlendorff C, Jensen BV, et al. (2014): MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311: 392-404.
38.
Li A, Yu J, Kim H, et al. (2013): MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 19: 3600-3610.
39.
Lu J, Getz G, Miska EA (2005): MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
40.
Binker BG, Binker-Cosen AA, Richards D, et al. (2009): EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. Biochem Biophys Res Commun 379: 445-450.
41.
Kwon JJ, Nabinger SC, Vega Z, et al. (2015): Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Scientific Reports 5: 11450-11472.
42.
Xuanbin W, Longchao X, Hongliang L, et al. (2015): The role of HMGB1 signalling pathway in the development and progression of hepatocellular carcinoma: A review. Int J Mol Sci 16: 22527-22540.
43.
Noguiera-Machado JA, de Oliviera Volpe CM (2012): HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov 6: 201-209.
44.
Rojas A, Delgado-Lopez F, Perez-Castro R, et al. (2016): HMGB-1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism. Tumour Biol 37: 3321-3329.
45.
Xu YL, Qian QL, Zong LZ, et al. (2014): High mobility group Box1 (HMGB1) is associated with progression and poor prognosis in pancreatic cancer. Gastroint Dig Syst 4: 1-7.
46.
Nativel B, Marimouton M, Thon-Hon V, et al. (2013): Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: Contribution to chronic inflammation in fat tissue. PLoS One 8: 1-11.
47.
Kang R, Zhang Q, Hou W, et al. (2014): Intracellular HMGB-1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology 146: 1097-1107.
48.
Musumeci D, Roviello GN, Montesarchio D (2014): An overview on HMGB-1 inhibitors as potential therapeutic agents in HMGB-1-related pathologies. Pharmacol Ther 141: 347-357.
49.
Kang R, Tang D, Schapiro NE, et al. (2014): The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33: 567-577.
50.
Angelopoulou E, Piperi C, Adamopoulos C, et al. (2016): Pivotal role of high-mobility group box 1 (HMGB1) signalling pathways in glioma development and progression. J Mol Med (Berl) 94: 867-874.
51.
Sharma S, Evans A, Hemers E (2016): Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box-1. Cell Tissue Res 365: 357-366.
52.
Van Beijnum JR, Buurman WA, Griffioen AW (2008): Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signalling pathways via high mobility group B1 (HMGB1). Angiogenesis 11: 91-99.
53.
Kishikawa T, Otsuka M, Ohno Motoko, et al. (2015): Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol 21: 8527-8540.
54.
Shing-Chun T, Yang-Chao Ch (2014): Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 20: 10825-10844.
55.
Inman KS, Francis AA, Murray NR (2014): Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol 20: 11160-11181.
56.
Wittwer Ch, Boeck S, Heinemann V, et al. (2013): Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 133: 2619-2630.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
